From challenges to solutions: A review of fourth-generation EGFR tyrosine kinase inhibitors to overcome the C797S triple mutation in non-small cell lung cancer
Authors:
- 19 December 2024
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 284, 117178
Abstract
No abstract availableKeywords
Funding Information
- Indian Council of Medical Research (IIRPIG-2023-0000318)
This publication has 79 references indexed in Scilit:
- The new N2, N4-diphenylpyridine-2,4-diamine deuterated derivatives as EGFR inhibitors to overcome C797S-mediated resistanceBioorganic Chemistry, 2024
- Lung cancer statistics, 2023Cancer, 2024
- Molecular analysis and systematic profiling of allosteric inhibitor response to clinically significant epidermal growth factor receptor missense mutations in non‐small cell lung cancerJournal of the Chinese Chemical Society, 2021
- Design, synthesis and evaluation of anti-proliferative activity of 2-aryl-4-aminoquinazoline derivatives as EGFR inhibitorsBioorganic Chemistry, 2021
- Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistancePharmacological Reports, 2020
- Dacomitinib: First Global ApprovalDrugs, 2018
- Crystal structure of EGFR T790M/C797S/V948R in complex with EAI045Biochemical and Biophysical Research Communications, 2018
- Allosteric Inhibitor TREA‐0236 Containing Non‐hydrolysable Quinazoline‐4‐one for EGFR T790M/C797S Mutants InhibitionBulletin of the Korean Chemical Society, 2018
- Discovery of EGF Receptor Inhibitors That Are Selective for the d746‐750/T790M/C797S Mutant through Structure‐Based de Novo DesignAngewandte Chemie, 2017
- Insight into the Inhibition of Drug‐Resistant Mutants of the Receptor Tyrosine Kinase EGFRAngewandte Chemie International Edition, 2016